The spleen is the largest lymphoid organ in the body and in addition to immunological functions plays important roles in erythrocyte filtration and platelet sequestration. Splenectomy is usually performed after trauma or as a therapeutic intervention in several haematological conditions but is associated with an increased risk of thrombosis and life-threatening infection (Luu et al., 2020). Despite the incidence of post-splenectomy thrombocytosis (PST) in approximately 80 % of cases, PST remains an intermittent prompt for requesting analysis of the JAK2 V617F and CALR mutations. These are the most commonly acquired mutations of the myeloproliferative neoplasm essential thrombocythaemia (ET) that is characterised by a persistent thrombocytosis and are present in approximately 80 % of all cases (Tefferi and Pardanani, 2019).
A retrospective audit was therefore performed in order to address the clinical value of screening for the JAK2 V617F and CALR mutations in patients presenting with PST. From January 2006 to December 2019 inclusive, requests received for JAK2 V617F or CALR mutation analysis were reviewed at a molecular diagnostic centre for haematological malignancies that receives approximately 1500 JAK2 V617F requests per annum. Clinical details of PTS were identified on 27 requests. The methodology for detection of the JAK2 V617F and CALR mutations was unchanged throughout the audit period. The JAK2 V617F was not detected in any of the 27 PST patients whereas CALR mutations were only sought in 12 and not detected in any of these patients.
While the impact on laboratory resources appears minimal, this short survey suggests that molecular testing for ET-associated mutations is not routinely warranted in patients with PST. It is not unreasonable to propose that in rare instances PST might mask ET and a review of the literature reveals a limited number of case reports in which this is the case (Wigton and Tersak, 2016; Akcan et al., 2018; Hatsuse et al., 2019). However, in all instances, splenectomy was preceded by an event clinically suggestive of ET (splenic rupture, splenomegaly with splenic infarcts or Budd-Chiari syndrome) and it may be in this recognisable but uncommon sequence of events that molecular screening for ET-associated mutations may be justified in a patient with PST.
The author declares no conflicts of interest.
[*] Corresponding Author:
Stephen E. Langabeer, Cancer Molecular Diagnostics, St. James’s Hospital, Dublin, Ireland; Phone: +353-1-4162413, Fax: +353-1-4103513, eMail: firstname.lastname@example.org